Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 3
---
16 |   13 |                                                                   |
| Operating Margin (%)                |       24 |   +8pp | +8pp |     33 |   +1pp | +1pp |                                                                   |
| Net finance expense                 |      349 |     27 |   25 |    305 |     -7 |   -9 | −Reduction                                                        
 in Core driven by lower short-term borrowing during the           
 quarter                                                           
 +Reported                                                         
 expense in Q3 2024 included a favourable fair value               
 adjustment                                                        |
| Tax rate (%)                        |       22 |      - |    - |     21 |   +2pp | +2pp | ∗Variations in the tax rate can be expected between               
 periods                                                           |
| EPS ($)                             |     1.64 |     77 |   70 |   2.38 |     14 |   12 |                                                                   |

For monetary values the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).

In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol beside an R&D expense comment indicates that the item increased R&D expenditure relative to the prior year period.

Corporate and business development

Listing harmonisation

As announced on 29 September 2025 and approved by shareholders on 3 November 2025, AstraZeneca will harmonise its share listing structure to deliver a global listing for global investors in a global company. It is expected that AstraZeneca shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange from 2 February 2026. For further details, see the Circular containing details of the Harmonised Listing Structure.

US investment plans

In October 2025, AstraZeneca announced having broken ground on its $4.5bn manufacturing facility in Rivanna Futures, Albemarle County, Virginia. This is part of the Company's plans to invest $50bn in US manufacturing and R&D by 2030, announced in July 2025.

The Virginia plant is expected to create approximately 3,600 direct and indirect jobs. It will produce drug substance for AstraZeneca's weight management and metabolic portfolio, including oral GLP-1 (AZD5004), baxdrostat, oral PCSK9